What is Chardan Capital’s Forecast for MNMD FY2025 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a research note issued on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will earn ($1.70) per share for the year. Chardan Capital has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). During the same quarter in the previous year, the company earned ($0.59) earnings per share.

Several other equities research analysts have also recently issued reports on MNMD. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Evercore ISI assumed coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 price target on the stock. Robert W. Baird reduced their price objective on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Finally, Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. Ten research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Mind Medicine (MindMed) currently has a consensus rating of “Buy” and a consensus target price of $25.11.

Mind Medicine (MindMed) Stock Performance

Shares of NASDAQ MNMD opened at $6.43 on Thursday. The firm’s 50-day moving average price is $7.28 and its 200-day moving average price is $6.95. Mind Medicine has a 52-week low of $5.03 and a 52-week high of $12.22. The company has a market cap of $484.62 million, a PE ratio of -2.85 and a beta of 2.57. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling

In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 6,836 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the sale, the insider now directly owns 446,177 shares of the company’s stock, valued at $3,007,232.98. This trade represents a 1.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 21,208 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the transaction, the chief executive officer now owns 856,556 shares in the company, valued at $5,773,187.44. The trade was a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,391 shares of company stock valued at $204,835. 2.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new position in shares of Mind Medicine (MindMed) during the third quarter worth $134,000. Charles Schwab Investment Management Inc. lifted its stake in Mind Medicine (MindMed) by 8.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 602,544 shares of the company’s stock worth $3,428,000 after purchasing an additional 46,187 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Mind Medicine (MindMed) during the 3rd quarter valued at about $242,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Mind Medicine (MindMed) by 22.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,226 shares of the company’s stock valued at $126,000 after purchasing an additional 4,079 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Mind Medicine (MindMed) by 0.5% in the third quarter. State Street Corp now owns 1,814,829 shares of the company’s stock worth $10,326,000 after purchasing an additional 9,782 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.